Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mezagitamab + bortezomib + lenalidomide + dexamethasone
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Intravenous, Oral
01
Overview
mezagitamab + bortezomib + lenalidomide + dexamethasone is an investigational combination regimen consisting of a monoclonal antibody (mezagitamab), a proteasome inhibitor (bortezomib), an immunomodulatory agent (lenalidomide), and a corticosteroid (dexamethasone). Mezagitamab is a fully human IgG1 monoclonal antibody targeting CD38, designed to deplete plasma cells, plasmablasts, and natural killer cells, with associated immunomodulatory effects[3][5]. Bortezomib inhibits the 26S proteasome, disrupting protein degradation in malignant cells and inducing apoptosis[1][6]. Lenalidomide exerts immunomodulatory, anti-angiogenic, and direct antineoplastic effects, including enhancing cytotoxic T cell and NK cell activity and inhibiting tumor-supporting blood vessel formation[4][6]. Dexamethasone, a synthetic corticosteroid, is used to manage inflammation and increase the antitumor effects of the other agents[4]. The combination aims to improve outcomes in relapsed/refractory multiple myeloma (RRMM) by synergistically targeting malignant plasma cells through complementary mechanisms, with mezagitamab providing additional immunomodulatory activity[5].
- Other names
- mezagitamab + bortezomib + lenalidomide + dexamethasone
02
Targets
GR (Glucocorticoid receptor)CD38 (Cluster of Differentiation 38)CRBN (Cereblon)26S proteasome
Beyond the preview
Go deeper on mezagitamab + bortezomib + lenalidomide + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mezagitamab + bortezomib + lenalidomide + dexamethasone.